

Unveiling the Interplay Between Depressive Symptoms' Alleviation and Quality of Life Improvement in Major Depressive Disorder: A Network Analysis Based on Longitudinal Data

Tong Guo^{1,2}, Yuan Feng^{1,2}, Jingjing Zhou^{1,2}, Linghui Meng^{1,2}, Xuequan Zhu^{1,2}, Xu Chen^{1,2}, Le Xiao^{1,2}, Lei Feng^{1,2}, Ling Zhang^{1,2}, Yu-Tao Xiang^{3,4}, Yan-Jie Zhao^{1,2}, Gang Wang^{1,2}

¹Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, People's Republic of China; ²Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, People's Republic of China; ³Unit of Psychiatry, Department of Public Health and Medicinal Administration, Faculty of Health Sciences, Institute of Translational Medicine, University of Macau, Taipa, Macao SAR, People's Republic of China; ⁴Centre for Cognitive and Brain Sciences, University of Macau, Taipa Macao SAR, People's Republic of China

Correspondence: Yan-Jie Zhao; Gang Wang, Email yzhao118@126.com; gangwangdoc@ccmu.edu.cn

Background: Understanding the dynamic relationship between depressive symptoms and quality of life (QOL) is essential in improving long-term outcomes for patients with Major Depressive Disorder (MDD). While previous studies often relied on cross-sectional data, there is a pressing need for stronger evidence based on longitudinal data to better inform the development of effective clinical interventions. By focusing on key depressive symptoms, such interventions have the potential to ultimately enhance QOL in individuals with MDD.

Methods: This multi-center prospective study, conducted between 2016 and 2020, enrolled outpatients and inpatients diagnosed with MDD across twelve psychiatric hospitals in China. Longitudinal data on Patient Health Questionnaire – 9 (PHQ-9) and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) was analyzed using an Extended Bayesian Information Criterion (EBIC) graphical least absolute shrinkage and selection operator (gLASSO) network model to explore the connections between depressive symptom changes and QOL changes. Flow network was applied to investigate relationships between individual symptom changes and overall QOL score change, as well as daily functional independence.

Results: This study included 818 participants with complete data after 8-week antidepressant treatment. Apart from the overlapping items from PHQ-9 and Q-LES-Q-SF, the three edges between “mood” (delta-QLES2) and “anhedonia” (delta-DEP1), between “physical health” (delta-QLES1) and “sleep problems” (delta-DEP3), and between “physical health” (delta-QLES1) and “sad mood” (delta-DEP2) were the most strong bridges between the cluster of depressive symptoms alleviation and the cluster of QOL change. “Anhedonia” (delta-DEP1), “sad mood” (delta-DEP2) and “loss of energy” (delta-DEP4) had the highest bridge strength between the alleviations of depressive symptoms and the total score change of Q-LES-Q-SF. Anhedonia had the greatest connection with participants' satisfaction with function in daily life.

Conclusion: This study highlighted the potential for developing highly effective interventions by targeting on central symptoms, thereby to ultimately improve QOL for patients with MDD.

Keywords: network analysis, patients with MDD, acute phase treatment, depressive symptoms, quality of life

Introduction

Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood, loss of interest, and feelings of helplessness. According to previous systematic meta-analyses, the global prevalence of MDD is approximately 4.4%-5.0%, and has become one of the leading causes of disability worldwide.^{1,2} In 2019, the Chinese Mental

Health Survey (CMHS) showed that the lifetime prevalence of MDD was about 3.4%.^{3,4} MDD poses a heavy burden on patients, families, and society and has become a major public health problem that needs to be addressed urgently.⁵

In contemporary healthcare, there is a shifting emphasis towards the assessment of medium- and long-term disease outcomes, notably the Quality of Life (QOL), rather than focusing solely on symptom alleviation.⁶ This shift aligns with a patient-centered approach, highlighting the importance of tailoring healthcare interventions to improve patients' overall QOL, addressing their unique needs and preferences. As healthcare continues to evolve, this emphasis on QOL will likely play a pivotal role in shaping treatment strategies and healthcare policies. While conventional pharmacotherapy and psychotherapy remain central to treating MDD, newer interventions such as esketamine, Electroconvulsive Therapy (ECT), and Transcranial Magnetic Stimulation (TMS) have shown promising results in managing MDD or treatment-resistant depression (TRD) in the long run, further highlighting the need to understand how symptom changes impact long-term quality of life outcomes in diverse patient populations.⁷⁻⁹

Network analysis, a newly emerging research methodology, is progressively gaining traction and finding broader application within the domains of psychiatry and psychology.¹⁰⁻¹² Unlike the traditional latent model that assumes psychiatric syndromes such as depression as an unobservable latent factor and individual depressive symptoms as independent observable manifestations of depression,^{13,14} the network approach possesses the capacity to offer a visually illuminating portrayal of the intricate interdependencies that exist among individual symptoms, thereby unveiling the insightful associations that underlie psychiatric syndromes at the symptom level.¹²

Several preceding cross-sectional studies have unequivocally demonstrated the interdependent relationships between depression and QOL at the level of individual symptoms.¹⁵⁻¹⁸ The findings stemming from these studies conclusively highlighted the potential for developing highly effective interventions by targeting on central symptoms, thereby to mitigate the detrimental effects of depression and ultimately to improve QOL for affected populations. Nevertheless, it is imperative to note that the aforementioned studies primarily relied on cross-sectional data, which inherently possesses limitations in capturing the dynamic changes over time of the core symptoms and their consequential impact on the improvement of QOL in patients with MDD, leaving a pronounced demand to be comprehensively explored and diligently addressed.

This study filled this research gap by using the longitudinal score changes in psychiatric scales over time as the main objects of network analysis, rather than the cross-sectional scores of psychiatric instruments. This study aims to construct the network model for the change in depressive symptoms and the change in QOL during the real-world acute-phase treatment process among patients with MDD, to explore the bridge symptoms connecting depression and QOL, and to provide stronger evidence for the potential of developing effective clinical interventions by focusing on key depressive symptoms to ultimately promote QOL in patients with MDD.

Methods

Study Setting and Participants

This is a post-hoc analysis of a study aiming at achieving the Optimization of Measurement-Based Care (OMBC) for MDD by establishing a comprehensive MBC framework based on all-round, continuous assessment for depression. The study protocol was published by Zhou J et al in 2022.¹⁹ This multi-center prospective real-word study was conducted from November 9, 2016, to December 30, 2020, in twelve psychiatric hospitals or psychiatric units of general hospitals in China. Outpatients and inpatients with MDD in this study in these twelve psychiatric hospitals or units who met the following eligibility criteria were consecutively invited to participate: 1) aged 18 to 65 years; 2) diagnosed with MDD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria; 3) total score of the 17-item Hamilton Rating Score for Depression (HAMD-17) ≥ 14 in baseline; 4) total score of the 16-item Quick Inventory of Depressive Symptoms – Self-Report (QIDS-SR16) ≥ 11 in baseline; 5) able to understand the purpose of this study and the contents of the psychiatric assessments in this study. Patients with severe physical diseases and female patients in pregnancy were excluded. Patients at high risk of suicidal ideation (determined by a HAMD-17 item-3 score ≥ 3 points) were excluded from this study. Patients were excluded if they had used antidepressants continuously for more than 7 days in the most recent 14 days before screening.

After screening, participants were prescribed with one of the following seven antidepressants for 12-week medical treatment: escitalopram, citalopram, paroxetine, fluvoxamine, sertraline, mirtazapine or fluoxetine. The choice and dose of the antidepressant treatments were determined by the clinical judgement of psychiatrists. Psychiatrists could choose aripiprazole as an augmentation therapy depending on the patient's condition. The participants were randomly assigned to the Measurement-Based Care (MBC) group and treatment as usual (TAU) group at a ratio of 2:1.¹⁹ Although the actual number of recruited participants exceeded the target sample in study protocol, sample attrition occurred during the follow-up period.^{19,20} Given that the network model analysis requires complete data for each node, and to balance the consideration of symptom recovery with the need for a robust sample size to support our conclusion, we opted to analyze the complete dataset from baseline to week 8 for this post-hoc analysis.

The protocol of this study was reviewed and approved by the Institutional Review Board (IRB) of all the participating centers, including Beijing Anding Hospital, Guangdong Mental Health Center, the First Affiliated Hospital of Harbin Medical University, the First Affiliated Hospital of Hebei Medical University, West China Hospital of Sichuan University, the First Affiliated Hospital of Kunming Medical University, Nanjing Brain Hospital Affiliated to Nanjing Medical University, the First Psychiatric Hospital of Harbin, Tongji Hospital of Tongji University, the First Hospital of Shanxi Medical University, Shenzhen Mental Health Center, and the Fourth Military Medical University of People's Liberation Army. Written informed consent was obtained from all participants before screening and all the other study procedures. This study was conducted following ethical principles for medical research involving human subjects in compliance with the Declaration of Helsinki.

Data Collection and Assessments Tools

Socio-demographic data including age, sex, education level, residence area (urban or rural), marital status and employment status of the participants were collected.

Severity of depressive symptoms was assessed using the validated Chinese version of the Patient Health Questionnaire – 9 (PHQ-9). The PHQ-9 consists of nine items, each rated on a frequency scale from 0 (not at all) to 3 (almost every day).^{21,22} Higher PHQ-9 scores represent more severe depression.²³ The psychometric properties of the PHQ-9 had been proved to be reliable in Chinese populations.^{24,25}

Overall quality of life (QOL) was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-Q-SF). Q-LES-Q-SF consisted of 16 self-report items, of which only the first 14 items yield a total score.²⁶ The last two items are stand-alone items that measures perceived satisfaction on medication and overall life, respectively. Every item in Q-LES-Q-SF ranges from 1 (very poor satisfaction) to 5 (very good satisfaction). The Chinese version of the Q-LES-Q-SF has been validated and widely used in Chinese population.^{27–29}

Data Analyses

An extended Bayesian Information Criterion (EBIC) model graphical least absolute shrinkage and selection operator (gLASSO) network model was constructed to explore the interconnective relationships between the changes in depressive symptoms and the changes in the first 14 item of Q-LES-Q-SF from baseline to week 8. In the network structure, the score change in each individual symptom was a “node”, and connections between the score changes in symptoms were “edges”. The centrality of the score change in each symptom was measured using strength and bridge strength. Strength is the sum of the absolute weights of the edges connecting a certain node to all the other nodes.³⁰ Bridge strength is the sum of the absolute weights of all the edges connecting a certain node to all the other nodes from the other cluster.^{31,32} The size of a node represented the strength of the score change in a particular symptom. The thickness of each edge represented the strength of the association between two nodes. The color of an edge reflected the direction of the association with green edges indicating positive associations and red edges indicating negative associations between nodes.

Network stability was examined via the correlation stability coefficient (CS-C) using a case-dropping 1000-time bootstrap method.^{33,34} The CS-C quantifies the maximum proportion of cases that can be dropped at random to retain, with 95% certainty, a correlation coefficient (r) of at least 0.7 between the centralities of the original network and the subsample network.³⁵ Preferably, a CS-C exceeds 0.5, with a minimum value requirement of 0.25.³⁵

A flow network was applied to investigate relationships between the score change in each individual depressive symptoms and Q-LES-Q-SF total score among the patients with MDD. To verify the results of the network analyses, generalized linear models were applied to explore the impact of the score change in each individual depressive symptom on the change in Q-LES-Q-SF total score while adjusting age and sex.

Network comparison tests (NCT) with Holm's correction for multiple comparisons were employed to investigate whether variations in socio-demographic factors (sex and age group, categorized using the median-split method) and clinical features (first episode or relapse, receiving TAU or MBC) led to significant differences to the EBIC gLASSO network model.

To explore the impact of depressive symptom recovery on the functional independence, a flow network was adopted on the changes in PHQ-9 scores and the 8th item from Q-LES-Q-SF (satisfactory level on ability to function in daily life).

All data analyses were conducted using Statistical Analysis System (SAS) version 9.4 (SAS Institute Inc., Cary, North Carolina, USA) and R version 4.3.1.³⁶ R packages used in this study were *networktools* version 1.2.3, *bootnet* version 1.4.3, *NetworkComparisonTest* version 2.2.2 and *qgraph* version 1.6.5.^{32,35,37,38}

Results

Socio-Demographic and Clinical Features of the Study Sample

In total, 818 patients with MDD were included in this study; of these, 555 (67.8%) were female. The mean age of the participants was 35.8±12.4 years. A majority of the participants were in the first episode of MDD (503/818; 61.5%). For the participants with recurrent MDD, they experienced an average of 2.86 MDD episodes, and the average duration of MDD was 5.61 years. About 14.2% of the participants (116/818) had a family history of mental disorders. Detailed description of the socio-demographic characteristics and clinical features of the study sample is shown in [Supplementary Table 1](#). The changes in PHQ-9 item scores and Q-LES-Q-SF item scores from baseline to week 8 are described in [Supplementary Table 2](#).

EBIC gLASSO Network Model

The network model for the change in PHQ-9 and change in Q-LES-Q-SF from baseline to week 8 is shown in [Figure 1](#). All edges between depressive symptom score changes and life quality score changes were negative. Nodes within the cluster of depressive symptoms were closely interconnected with those within the cluster of life quality generally. The score changes in the 2nd item (mood), 14th item (overall sense of wellbeing), 7th item (leisure time activities) and 5th item (social relationships) in Q-LES-Q-SF had the highest strength in this network ([Figure 2](#)).

The edge between “physically getting around” (delta-QLES12) and “psychomotor signs” (delta-DEP8), the edge between “mood” (delta-QLES2) and “sad mood” (delta-DEP2), the edge between “mood” (delta-QLES2) and “anhedonia” (delta-DEP1), the edge between “physical health” (delta-QLES1) and “sleep problems” (delta-DEP3), and the edge between “physical health” (delta-QLES1) and “sad mood” (delta-DEP2) had the highest edge weights. The weighted adjacency matrix for this network model is displayed on [Supplementary Table 3](#).

The CS-C for strength in this network model was 0.751, indicating that the strength values in this network remained stable after dropping 75.1% of the study sample ([Supplementary Figure 1](#)). The bootstrapped confidence intervals of edge weights, bootstrapped edge weight difference tests and bootstrapped node strength tests were displayed in [Supplementary Figures 2–4](#).

Flow Network Model

The flow network model for the change in PHQ-9 and change in Q-LES-Q-SF total score from baseline to week 8 is shown in [Figure 3](#). The score changes in “anhedonia” (delta-DEP1), “sad mood” (delta-DEP2) and “loss of energy” (delta-DEP4) had the highest bridge strength between the cluster of depressive symptoms' alleviations and the total score change of Q-LES-Q-SF ([Figure 4](#)), indicating that the symptom alleviations in these three items had the strongest connection with the improvement of QOL. The weighted adjacency matrix for this flow network model is displayed on [Supplementary Table 4](#).




Figure 1 Network model for the change in PHQ-9 and change in Q-LES-Q-SF from baseline to week 8.

Notes: The size of each node indicates the relative level of strength. Green edges indicate positive associations; red edges indicate negative associations. Delta refers to score change from baseline to week 8.




Figure 2 Strength and bridge strength of the network model for the change in PHQ-9 and change in Q-LES-Q-SF from baseline to week 8 (z-score).

The CS-C for bridge strength in this network model was 0.751, indicating that the bridge strength values in this network remained stable after dropping 75.1% of the study sample ([Supplementary Figure 5](#)). The bootstrapped confidence intervals of edge weights, bootstrapped edge weight difference tests and bootstrapped node strength tests were displayed in [Supplementary Figures 6–8](#).




Figure 3 Flow network model for the change in PHQ-9 and change in Q-LES-Q-SF total score from baseline to week 8.

Notes: The size of each node indicates the relative level of strength. Green edges indicate positive associations; red edges indicate negative associations. Delta refers to score change from baseline to week 8.




Figure 4 Strength and bridge strength of the network model for the change in PHQ-9 and change in Q-LES-Q-SF total score from baseline to week 8 (z-score).

The Impact of the Alleviations in Each Depressive Symptom on the Improvement of QOL

The results of generalized linear models showed that the alleviations in all the nine depressive symptoms had significant impact on the improvement of QOL after adjusting for age and sex. Anhedonia (DEP-1), sad mood (DEP-2) and loss of

energy (DEP-4) had the highest r-square values and lowest Akaike Information Criterion (AIC) values, which is consistent with the finding from the flow network model ([Supplementary Table 5](#)).

Subgroup Analyses Based on Socio-Demographic Factors and Clinical Features

Comparisons of networks based on sex, age groups (split by the median age), episode status (first episode or relapse), and treatment type (TAU or MBC) are displayed in [Figure 5](#). The invariance tests on network structure, global strength, and edge weights showed that those network features were consistent between subgroups based on sex, episode status, and treatment type, with the exception of age group. The network invariance test showed that the network structure was statistically different between younger and older participants (test statistic $M=0.239$, $p=0.012$) and the maximum difference lies in the edge between the first item (physical health) and second item (mood) from Q-LES-Q-SF. This indicates that older participants exhibit significantly stronger connections between their satisfaction in physical health and their mood status.

The Impact of the Alleviations in Each Depressive Symptom on the Functional Independence

The flow network model for the change in PHQ-9 and change in functional independence (identified as the 8th item from Q-LES-Q-SF, ie, satisfactory level on function in daily life) from baseline to week 8 is shown in [Figure 6](#). Alleviation on anhedonia had the greatest connection with participants' satisfactory level of function in daily life. The CS-C for bridge




Figure 5 Network comparisons based on subgroups by socio-demographic factors and clinical features.

Notes: (a) subgroup analysis based on age (categorized by median of age: 33.004 years old); (b) subgroup analysis based on sex; (c) subgroup analysis based on episode status; (d) subgroup analysis based on treatment type. Delta refers to score change from baseline to week 8.




Figure 6 Flow network model for the change in PHQ-9 and change in functional Independence from baseline to week 8.

Notes: Functional independence was identified as the 8th item from Q-LES-Q-SF, ie, satisfactory level on ability to function in daily life. The size of each node indicates the relative level of strength. Green edges indicate positive associations; red edges indicate negative associations. Delta refers to score change from baseline to week 8.

strength in this network model was 0.751, indicating that the bridge strength values in this network remained stable after dropping 75.1% of the study sample ([Supplementary Figure 9](#)).

Discussion

This study found that apart from the overlapping items from PHQ-9 and Q-LES-Q-SF, the edge between “mood” (delta-QLES2) and “anhedonia” (delta-DEP1), the edge between “physical health” (delta-QLES1) and “sleep problems” (delta-DEP3), and the edge between “physical health” (delta-QLES1) and “sad mood” (delta-DEP2) were the most strong bridges between the cluster of depressive symptoms alleviation and the cluster of QOL change. “Anhedonia” (DEP-1), “sad mood” (DEP-2) and “loss of energy” (DEP-4) had the highest bridge strength between the alleviations of depressive symptoms and the total score change of Q-LES-Q-SF.

Prior research had revealed that the severities of anhedonia and sadness were highly correlated, which was consistent with the findings in our research. “Anhedonia” and “sad mood” are two required symptoms for diagnosing major depressive disorder according to DSM-IV.^{11,39–42} The strong link between anhedonia and sadness could be explained by that anhedonia may prevent experiences of pleasure and interest in life and work, which may increase sadness later, given that patients with MDD usually lack the capability to complete tasks and fulfill wishes.⁴⁰ From the perspective of core symptoms of MDD, the onset of one symptom may trigger another over time.^{11,43}

The coexistence of anhedonia and sad mood in the majority of MDD could also be understood from the perspective of neurobiological and neuroimaging studies.^{44–47} Low dopaminergic activity has been reported in patients with MDD, as well as those with sad mood and low hedonic tone.⁴⁸ Neuro-imaging studies have reported decreased striatal activation in hedonic experience, and the prefrontal cortices play a major role in mood regulation in patients with MDD.^{49,50} The pathway of mood and hedonic experience could have an up and down mutual interaction. However, there was no

correlation between sad mood and anhedonia in some patients with MDD, because of their own neuronal bases with their own circuitries.⁵⁰

This study found that good sleep plays an essential role in physical health. Sleep problems can increase the risk of health problems such as mental health, chronic disease prevalence and mortality. The strong association between “physical health” and “sleep problems” was found in our current study, which was similar to previous studies.^{51–53} This strong connection could be explained in several aspects. First of all, the theory of cognitive-emotional hyperarousal claims that sleep problems are the results of dysfunctional and abnormal excitement processes.^{54–56} Second, several studies suggest that sufficient sleep may contribute to hormonal balance and impact cortisol secretion.^{57,58} Deprivation of sleep may gradually change neuroendocrine systems especially the hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, associating with mental health such as depression which is highly stress-related.⁵⁸ The relationship between stress systems and sleep is complex and bidirectional.⁵⁷ This finding reminds psychiatrists to pay more attention to sleep problems so as to get a better health status and QOL for patients with MDD.

We found that “physical health” from Q-LES-Q-SF and “sad mood” from PHQ-9 had strong connection with each other, which were consistent with previous studies.^{11,43} It was proved that physical health was closely linked to positive subjective wellbeing which might be a protective factor for health.⁵⁹ Depressed mood is a serious adverse factor that affects peoples’ physical health. In turn, the long-term condition (LTC) could also affect emotions by complex conditions, cognitive symptoms, loss of function, reducing independence, and hinder the rehabilitation process.⁶⁰ There is growing evidence that both physical health and depression have marked lifestyle-driven components.^{61–63} The mechanisms may include gut–brain axis and its effect on the modulation of inflammation and oxidative stress. Individual bioactive molecules have also been considered.⁶³ It is noteworthy that depression is often coexisted with chronic diseases, such as cardiovascular disease, dementia, and cancer.⁶⁴ For some individuals, chronic diseases were capable of triggering depression. For some people, chronic diseases were running alongside the depression. For some patients with depression, sad emotions may be a risk factor for developing physical illnesses.^{60,64} Patients with MDD often experience somatic symptoms. They often seek their first visit to a general hospital with physical symptoms.^{65–69} It provides an important implication for psychiatrists that they should not only pay attention to the patient’s physical condition but also do not overlook the interaction between physical illness and depression. Our findings point to the meaningfulness to targeted therapies that address one of these bridge symptoms may improve the other symptoms. There is a need for promising interventions which ought to be developed to ensure physical and mental health.

This study found that older participants exhibit significantly stronger connections between their satisfaction in physical health and their mood status. This might be due to that as people age, they tend to experience more health-related issues, such as chronic illnesses, mobility limitations, and general physical decline. These physical health challenges can significantly impact their daily life and overall well-being, making them more sensitive to their physical health status. When older adults feel physically healthy, they are more likely to experience a positive mood, whereas poor physical health can lead to feelings of frustration, sadness, or hopelessness. Meanwhile, in older adults, physical and mental health are closely interconnected.⁷⁰ Physical conditions can lead to psychological distress, and vice versa. For example, chronic pain or disability can contribute to feelings of depression or anxiety, while a positive physical health status can enhance mood and overall life satisfaction.^{71,72}

This study found that anhedonia had the greatest connection with participants’ satisfaction with function in daily life. Anhedonia, which is the inability to experience pleasure or interest in activities that were once enjoyable, is a core symptom of MDD.⁷³ It directly impacts an individual’s ability to engage in and derive satisfaction from daily life activities.⁷⁴ Here are several potential explanations for this strong connection. First, anhedonia reduces motivation and the desire to participate in daily activities, including work, social interactions, and hobbies.⁷⁵ This decline in engagement naturally leads to a decreased sense of satisfaction with one’s daily functioning.⁷⁶ Second, anhedonia diminishes the ability to feel pleasure, which means that even if individuals attempt to engage in daily activities, they do not experience the usual positive reinforcement that comes from these activities.^{77,78} Over time, this lack of positive reinforcement can erode their overall satisfaction with life. Third, because anhedonia can lead to a lack of interest in self-care, household tasks, or professional responsibilities, it can result in reduced productivity and an overall sense of dysfunction in daily life.^{77,79} This can make it difficult for individuals to meet their own or others’ expectations, further decreasing their

satisfaction with daily functioning.⁸⁰ Moreover, anhedonia often leads to social withdrawal, as individuals lose interest in maintaining relationships or participating in social activities.^{75,81} This isolation can negatively affect their overall quality of life and their perception of how well they are functioning in their daily lives.⁸²

Depression is a multifaceted disorder that is often shaped by the socio-cultural context in which it occurs. Cultural norms and values can affect how symptoms are perceived, expressed, and managed, which in turn influences treatment outcomes. For example, in east Asian cultures, emotional distress may be more likely to manifest as physical symptoms, leading to differences in how depression is diagnosed and treated.^{83,84} Additionally, access to mental health care, societal stigma, and the availability of social support vary across regions, which can further modulate the course of the disorder and the QOL of the patients.^{85,86}

Given that our study was conducted within a specific cultural and geographical context, we acknowledge that the generalizability of our findings to other settings, such as rural areas or Western countries, may be limited. Therefore, while our results provide valuable insights into the treatment of MDD within the studied population, further research is needed to explore how these findings might translate to diverse populations with varying cultural backgrounds.

The strengths of this study included its multi-center prospective study design, visual depiction of depression-QOL interplays at symptom level, and focusing on symptom changes during real-world acute-phase treatment process. However, this study has several methodological limitations. First, the depression cluster in this network structure includes only the nine classical depressive symptoms. Therefore, including other facets of depressive symptoms might generate different patterns of inter-connective relationships. Second, the items from Q-LES-Q-SF have some overlaps with the items from PHQ-9, which might obscure the real connections. Third, this study focused on a specific population, ie, patients with MDD aged 18 to 65 years, excluding elderly individuals and those with chronic diseases. This approach led to a younger cohort, predominantly experiencing their first episode of depression, with fewer comorbidities. This creates a more restricted sample, which may not fully represent the broader MDD population. Given this limitation, the findings from this study may not be entirely generalizable to the entire population of individuals with MDD, particularly older adults, those with chronic, refractory, or recurrent MDD, and patients from western countries. Cultural norms, access to healthcare, and socio-economic conditions can vary significantly across different regions, potentially affecting the expression and progression of depressive symptoms. The distinct characteristics and treatment need of these groups highlight the importance of caution when extrapolating our results to more diverse patient populations. Furthermore, the recruitment model used in our study was hospital-based, focusing on patients from a psychiatric setting. This likely resulted in the inclusion of individuals with more severe depressive symptoms compared to those who might be seen in a community setting. If the study had been conducted on a community basis, the results might have differed, potentially capturing a wider range of symptom severity and demographic diversity. This could influence both the depressive symptom response and QOL outcomes observed. Further research that includes a broader range of populations, especially geriatric patients, those with chronic or recurrent MDD, and community-based samples, is essential to validate our findings and ensure that they are applicable across diverse clinical settings.

Recent advancements in rapid-acting antidepressants, such as ketamine, esketamine, and emerging psychedelic therapies like psilocybin, have shown promising results in alleviating depressive symptoms, particularly in treatment-resistant cases.^{87,88} While these interventions highlight the evolving landscape of depression treatment, our study focuses on more traditional pharmacological approaches, underscoring the need for future research to explore how novel therapies might interact with or complement standard treatment modalities in enhancing quality of life outcomes.

To be conclusive, this study found that “anhedonia”, “sleep problems” and “sad mood” might be the core depressive symptoms to be targeted for promoting QOL in patients with MDD. By using the longitudinal data, this study highlighted the potential for developing highly effective interventions by targeting on central symptoms, thereby to reduce adverse effects of depression and ultimately to improve QOL for affected populations.

Acknowledgments

The authors are grateful to all participants and clinicians involved in this study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

The study was supported by the National Key Research and Development Program of China (No. 2016YFC1307200), Beijing Scholar 2021 (No. 063), Beijing Hospitals Authority Youth Programme (No. QML20211902), Beijing High Level Public Health Technology Talent Construction Project (Discipline Backbone-01-028), and 2023 Sprout Science and Technology Innovation Fund by Beijing Anding Hospital, Capital Medical University (No. 12-2024 and No. 13-2024).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. *Psychol Med*. 2013;43(3):471–481. doi:10.1017/S0033291712001511
2. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. *PLoS Med*. 2013;10(11):e1001547. doi:10.1371/journal.pmed.1001547
3. Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. *Lancet Psychiatry*. 2019;6(3):211–224. doi:10.1016/S2215-0366(18)30511-X
4. Lu J, Xu X, Huang Y, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. *Lancet Psychiatry*. 2021;8(11):981–990. doi:10.1016/S2215-0366(21)00251-0
5. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the global burden of disease study 2010. *Lancet*. 2013;381(9882):1987–2015. doi:10.1016/S0140-6736(13)61097-1
6. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. *Harv Rev Psychiatry*. 2011;19(5):229–239. doi:10.3109/10673229.2011.614099
7. Huang XB, Zheng W. Ketamine and electroconvulsive therapy for treatment-refractory depression. *Alpha Psychiatry*. 2023;24(6):244–246. doi:10.5152/alphapsychiatry.2023.231358
8. Wen KS, Zheng W. Optimization strategies of transcranial magnetic stimulation in major depressive disorder. *Alpha Psychiatry*. 2023;24(6):270–272. doi:10.5152/alphapsychiatry.2023.231401
9. Yuan S, Luo X, Zhang B. Individualized repetitive transcranial magnetic stimulation for depression based on magnetic resonance imaging. *Alpha Psychiatry*. 2023;24(6):273–275. doi:10.5152/alphapsychiatry.2023.231412
10. Borsboom D. A network theory of mental disorders. *World Psychiatry*. 2017;16(1):5–13. doi:10.1002/wps.20375
11. Cramer AO, Waldorp LJ, van der Maas HL, Borsboom D. Comorbidity: a network perspective. *Behav Brain Sci*. 2010;33(2–3):137–150. doi:10.1017/S0140525X09991567
12. Borsboom D, Cramer AO. Network analysis: an integrative approach to the structure of psychopathology. *Annu Rev Clin Psychol*. 2013;9(1):91–121. doi:10.1146/annurev-clinpsy-050212-185608
13. Everett B. *An Introduction to Latent Variable Models*. Springer Science & Business Media; 2013.
14. Schmittmann VD, Cramer AO, Waldorp LJ, Epskamp S, Kievit RA, Borsboom D. Deconstructing the construct: a network perspective on psychological phenomena. *New Ideas Psychol*. 2013;31(1):43–53. doi:10.1016/j.newideapsych.2011.02.007
15. Zhao Y-J, Zhang L, Feng Y, et al. Prevalence of depression and its association with quality of life among guardians of hospitalized psychiatric patients during the COVID-19 pandemic: a network perspective. *Front Psychiatry*. 2023;14.
16. Zhao Y-J, Zhang S-F, Li W, et al. Associations between depressive symptoms and quality of life among residents of Wuhan, China during the later stage of the COVID-19 pandemic: a network analysis. *J Affect Disord*. 2022;318:456–464. doi:10.1016/j.jad.2022.08.104
17. Lin Y, Bai W, Liu HH, et al. Prevalence, correlates, and network analysis of depression and its association with quality of life in survivors with myocardial infarction during the COVID-19 pandemic. *J Affect Disord*. 2023;336:106–111. doi:10.1016/j.jad.2023.05.086
18. Si TL, Chen P, Zhang L, et al. Depression and quality of life among Macau residents in the 2022 COVID-19 pandemic wave from the perspective of network analysis. *Front Psychol*. 2023;14:1164232. doi:10.3389/fpsyg.2023.1164232
19. Zhou J, Wang X, Yang J, et al. Optimization of measurement-based care (OMBC) for depression based on all-round and continuous assessment: rationale and protocol for a multicenter randomized control clinical trial. *Trials*. 2022;23(1):367. doi:10.1186/s13063-022-06295-9
20. Zhou J, Zhou J, Feng L, et al. The associations between depressive symptoms, functional impairment, and quality of life, in patients with major depression: undirected and bayesian network analyses. *Psychol Med*. 2022;53(14):1–13. doi:10.1017/S0033291722003385
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606–613. doi:10.1046/j.1525-1497.2001.016009606.x
22. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *JAMA*. 1999;282(18):1737–1744. doi:10.1001/jama.282.18.1737

23. Chen MM, Sheng L, Qu S. Diagnostic test of screening depressive disorder in general hospital with the patient health questionnaire (in Chinese). *Journal of Chinese Mental Health*. 2015;29(4):241–245.
24. Wang W, Bian Q, Zhao Y, et al. Reliability and validity of the Chinese version of the patient health questionnaire (PHQ-9) in the general population. *Gen Hosp Psychiatry*. 2014;36(5):539–544. doi:10.1016/j.genhosppsych.2014.05.021
25. Xu Y, Wu HS, Xu YF. The application of patient health questionnaire 9 in community elderly population: reliability and validity. *Shanghai Arch Psychiatry*. 2007;19(05):257–259+276.
26. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction Questionnaire: a new measure. *Psychopharmacol Bull*. 1993;29(2):321–326.
27. Tang M-Q, Qiu H-M, Jian J. Reliability and validity of the quality of life enjoyment and satisfaction questionnaire - short form (Q-LES-Q-SF) in Chinese patients with mental disorders (in Chinese). *Chinese Mental Health Journal*. 2010;24(09):680–684.
28. Gao H-Y, Li S, Chen L, Tang L-M, Shou J. Reliability and validity of Chinese version of the short form of quality of life enjoyment and satisfaction questionnaire for elderly patients (in Chinese). *Chinese Journal of General Practice*. 2018;17(8):601–606.
29. Cheng -Y-Y, Tang M-Q. Reliability and validity of the Q-LES-Q-SF in patients with anxiety disorders (in Chinese). *Journal of Shandong University*. 2011;49(07):147–150.
30. Valente TW. Network interventions. *Science*. 2012;337(6090):49–53. doi:10.1126/science.1217330
31. Jones PJ, Ma R, McNally RJ. Bridge centrality: a network approach to understanding comorbidity. *Multivariate Behav Res*. 2021;56(2):353–367. doi:10.1080/00273171.2019.1614898
32. Jones P. networktools: tools for identifying important nodes in networks. R package version 1.2.3. Available from <https://CRAN.R-project.org/package=networktools>. 2020. Accessed September 30, 2023.
33. Chernick MR. *Bootstrap Methods: A Guide for Practitioners and Researchers, 2nd Edition*. Hoboken, New Jersey: John Wiley & Sons; 2007.
34. Costenbader E, Valente TW. The stability of centrality measures when networks are sampled. *Soc Networks*. 2003;25(4):283–307. doi:10.1016/S0378-8733(03)00012-1
35. Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: a tutorial paper. *Behav Res Methods*. 2018;50(1):195–212. doi:10.3758/s13428-017-0862-1
36. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from <https://www.R-project.org>. 2020. Accessed September 30, 2023.
37. Epskamp S, Cramer AO, Waldorp LJ, Schmittmann VD, Borsboom D. qgraph: network visualizations of relationships in psychometric data. *J Stat Softw*. 2012;48(4):1–18. doi:10.18637/jss.v048.i04
38. van Borkulo CD, Boschloo L, Kossakowski JJ, et al. Comparing network structures on three aspects: a permutation test. *J Stat Softw*. 2017.
39. Gao K, Sweet J, Su M, Calabrese JR. Depression severity and quality of life of qualified and unqualified patients with a mood disorder for a research study targeting anhedonia in a clinical sample. *Asian J Psychiatry*. 2017;27:40–47. doi:10.1016/j.ajp.2017.02.013
40. Garabiles MR, Shen ZZ, Yang L, Chu Q, Hannam K, Hall BJ. Investigating the physical and mental health nexus: a network analysis of depression, cardiometabolic health, bone mass, and perceived health status among Filipino domestic workers. *Int J Behav Med*. 2023;30(2):234–249. doi:10.1007/s12529-022-10087-5
41. Beard C, Millner AJ, Forgeard MJC, et al. Network analysis of depression and anxiety symptom relationships in a psychiatric sample. *Psychol Med*. 2016;46(16):3359–3369. doi:10.1017/S0033291716002300
42. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (4th Ed. Text Rev.)*. Arlington, VA: American Psychiatric Publishing, Inc.; 2000.
43. HMv L, Schoevers RA, Kendler KS, Jonge P, Romeijn J-W. PSYCHIATRIC COMORBIDITY DOES NOT ONLY DEPEND ON DIAGNOSTIC THRESHOLDS: AN ILLUSTRATION WITH MAJOR DEPRESSIVE DISORDER AND GENERALIZED ANXIETY DISORDER. *Depress Anxiety*. 2016;33(2):143–152. doi:10.1002/da.22453
44. Becker S, Bräscher A-K, Bannister S, et al. The role of hedonics in the human affectome. *Neurosci Biobehav Rev*. 2019;102:221–241. doi:10.1016/j.neubiorev.2019.05.003
45. Chuan-Peng H, Huang Y, Eickhoff SB, Peng K, Sui J. Seeking the “beauty center” in the brain: a meta-analysis of fMRI studies of beautiful human faces and visual art. *Cognitive, Affective & Behavioral Neuroscience*. 2020;20(6):1200–1215. doi:10.3758/s13415-020-00827-z
46. Chung YS, Barch D. Anhedonia is associated with reduced incentive cue related activation in the basal ganglia. *Cognitive, Affective & Behavioral Neuroscience*. 2015;15(4):749–767. doi:10.3758/s13415-015-0366-3
47. Harvey P-O, Pruessner J, Czechowska Y, Lepage M. Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. *Mol Psychiatry*. 2007;12(8):767–775. doi:10.1038/sj.mp.4002021
48. Booij L, Does A, Haffmans PMJ, Riedel WJ, Fekkes D, Blom MJB. The effects of high-dose and low-dose tryptophan depletion on mood and cognitive functions of remitted depressed patients. *J Psychopharmacol*. 2005;19(3):267–275. doi:10.1177/0269881105051538
49. Ferenczi EA, Zalocusky KA, Liston C, et al. Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior. *Science*. 2016;351(6268):9698.
50. Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. *Neuropsychiatr Dis Treat*. 2016;12:2149–2164. doi:10.2147/NDT.S111818
51. Lee M-S, Shin J-S, Lee J, et al. The association between mental health, chronic disease and sleep duration in Koreans: a cross-sectional study. *BMC Public Health*. 2015;15(1):1200. doi:10.1186/s12889-015-2542-3
52. Kim J-M, Stewart R, Kim S-W, Yang S-J, Shin I-S, Yoon J-S. Insomnia, depression, and physical disorders in late life: a 2-year longitudinal community study in Koreans. *Sleep*. 2009;32(9):1221–1228. doi:10.1093/sleep/32.9.1221
53. Xiang S, Dong J, Li X, Li L. Association between sleep duration, physical activity, and mental health disorders: a secondary analysis of the national survey of children's health 2017-2018. *Biomed Res Int*. 2021;2021:5585678. doi:10.1155/2021/5585678
54. Khazaie H, Zakiei A, McCall WV, et al. Relationship between sleep problems and self-injury: a systematic review. *Behav Sleep Med*. 2021;19(5):689–704. doi:10.1080/15402002.2020.1822360
55. Sadler P, McLaren S, Klein B, Jenkins M, Harvey J. Cognitive behaviour therapy for older adults experiencing insomnia and depression in a community mental health setting: study protocol for a randomised controlled trial. *Trials*. 2015;16(1):538. doi:10.1186/s13063-015-1066-6
56. Harvey AG, Tang NKY. (Mis)perception of sleep in insomnia: a puzzle and a resolution. *Psychol Bull*. 2012;138(1):77–101. doi:10.1037/a0025730

57. Meerlo P, Sgoifo A, Suchecki D. Restricted and disrupted sleep: effects on autonomic function, neuroendocrine stress systems and stress responsivity. *Sleep Med Rev*. 2008;12(3):197–210. doi:10.1016/j.smrv.2007.07.007
58. Minkel J, Moreta M, Muto J, et al. Sleep deprivation potentiates HPA axis stress reactivity in healthy adults. *Health Psychol*. 2014;33(11):1430–1434. doi:10.1037/a0034219
59. Lyubomirsky S, King L, Diener E. The benefits of frequent positive affect: does happiness lead to success? *Psychol Bull*. 2005;131(6):803–855. doi:10.1037/0033-2909.131.6.803
60. Poole L, Frost R, Rowlands H, Black G. Experience of depression in older adults with and without a physical long-term condition: findings from a qualitative interview study. *BMJ Open*. 2022;12(2):e056566. doi:10.1136/bmjopen-2021-056566
61. Marx W, Lane MM, Hockey M, et al. Diet and depression: future needs to unlock the potential. *Mol Psychiatry*. 2022;27(2):778–780. doi:10.1038/s41380-021-01360-2
62. Jacka FN, Pasco JA, Mykletun A, et al. Association of Western and traditional diets with depression and anxiety in women. *Am J Psychiatry*. 2010;167(3):305–311. doi:10.1176/appi.ajp.2009.09060881
63. Godos J, Currenti W, Angelino D, et al. Diet and mental health: review of the recent updates on molecular mechanisms. *Antioxidants*. 2020;9(4):346. doi:10.3390/antiox9040346
64. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *Med J Aust*. 2009;190(S7):S54–60. doi:10.5694/j.1326-5377.2009.tb02471.x
65. Aoki A, Nagate M, Utsumi K, et al. Can we determine depressive conditions on the basis of somatic symptoms? A cross-sectional study of depressive conditions among Japanese patients at a university hospital general medicine clinic. *Intern Med*. 2012;51(11):1335–1340. doi:10.2169/internalmedicine.51.7328
66. Hung C-I, Liu C-Y, Wang S-J. Migraine predicts physical and pain symptoms among psychiatric outpatients. *J Headache Pain*. 2013;14(1):19. doi:10.1186/1129-2377-14-19
67. Li X, Zhang H, Han X, et al. Predictive potential of somatic symptoms for the identification of subthreshold depression and major depressive disorder in primary care settings. *Front Psychiatry*. 2023;14:999047. doi:10.3389/fpsy.2023.999047
68. Zheng F, Duan Y, Li J, et al. Somatic symptoms and their association with anxiety and depression in Chinese patients with cardiac neurosis. *J Int Med Res*. 2019;47(10):4920–4928. doi:10.1177/0300060519869711
69. Zhu C, Ou L, Geng Q, et al. Association of somatic symptoms with depression and anxiety in clinical patients of general hospitals in Guangzhou, China. *Gen Hosp Psychiatry*. 2012;34(2):113–120. doi:10.1016/j.genhosppsych.2011.09.005
70. Das P, Naylor C, Majeed A. Bringing together physical and mental health within primary care: a new frontier for integrated care. *J R Soc Med*. 2016;109(10):364–366. doi:10.1177/0141076816665270
71. Børso B, Peolsson M, Gerdle B. The complex interplay between pain intensity, depression, anxiety and catastrophising with respect to quality of life and disability. *Disabil Rehabil*. 2009;31(19):1605–1613. doi:10.1080/09638280903110079
72. Lerman SF, Rudich Z, Brill S, Shalev H, Shahar G. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. *Psychosom Med*. 2015;77(3):333–341. doi:10.1097/PSY.0000000000000158
73. Auerbach RP, Pagliaccio D, Pizzagalli DA. Toward an improved understanding of anhedonia. *JAMA Psychiatry*. 2019;76(6):571–573. doi:10.1001/jamapsychiatry.2018.4600
74. Pizzagalli DA. Toward a better understanding of the mechanisms and pathophysiology of anhedonia: are we ready for translation? *Am J Psychiatry*. 2022;179(7):458–469. doi:10.1176/appi.ajp.20220423
75. Barkus E. The Effects of Anhedonia in Social Context. *Curr Behav Neurosci Rep*. 2021;8(3):77–89. doi:10.1007/s40473-021-00232-x
76. Watson R, Harvey K, McCabe C, Reynolds S. Understanding anhedonia: a qualitative study exploring loss of interest and pleasure in adolescent depression. *Eur Child Adolesc Psychiatry*. 2020;29(4):489–499. doi:10.1007/s00787-019-01364-y
77. Khazanov GK, Forbes CN, Dunn BD, Thase ME. Addressing anhedonia to increase depression treatment engagement. *Br J Clin Psychol*. 2022;61(2):255–280. doi:10.1111/bjc.12335
78. Chase HW, Frank MJ, Michael A, Bullmore ET, Sahakian BJ, Robbins TW. Approach and avoidance learning in patients with major depression and healthy controls: relation to anhedonia. *Psychol Med*. 2010;40(3):433–440. doi:10.1017/S0033291709990468
79. Bredemeier K, Berenbaum H, Brockmole JR, Boot WR, Simons DJ, Most SB. A load on my mind: evidence that anhedonic depression is like multi-tasking. *Acta Psychol*. 2012;139(1):137–145. doi:10.1016/j.actpsy.2011.11.007
80. Rutherford AV, McDougall SD, Joormann J. "Don't [ruminate], be happy": a cognitive perspective linking depression and anhedonia. *Clin Psychol Rev*. 2023;101:102255. doi:10.1016/j.cpr.2023.102255
81. Setterfield M, Walsh M, Frey AL, McCabe C. Increased social anhedonia and reduced helping behaviour in young people with high depressive symptomatology. *J Affect Disord*. 2016;205:372–377. doi:10.1016/j.jad.2016.08.020
82. Kwapiil TR, Silvia PJ, Barrantes-Vidal N. Social anhedonia and solitude. *The Handbook of Solitude*. 2013;369–390.
83. Yen S, Robins CJ, Lin N. A cross-cultural comparison of depressive symptom manifestation: china and the United States. *J Consult Clin Psychol*. 2000;68(6):993. doi:10.1037/0022-006X.68.6.993
84. Ryder AG, Yang J, Zhu X, et al. The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America? *J Abnorm Psychol*. 2008;117(2):300. doi:10.1037/0021-843X.117.2.300
85. Chen JA, Hung GC, Parkin S, Fava M, Yeung AS. Illness beliefs of Chinese American immigrants with major depressive disorder in a primary care setting. *Asian J Psychiatr*. 2015;13:16–22. doi:10.1016/j.ajp.2014.12.005
86. Sun Y, Chen G, Wang L, et al. Perception of stigma and its associated factors among patients with major depressive disorder: a multicenter survey from an asian population. *Front Psychiatry*. 2019;10:321. doi:10.3389/fpsy.2019.00321
87. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. *N Engl J Med*. 2022;387(18):1637–1648. doi:10.1056/NEJMoa2206443
88. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. *Am J Psychiatry*. 2021;178(5):383–399. doi:10.1176/appi.ajp.2020.20081251

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>